(1, 2).
Increasing 13 N-NH3 reimbursement
In the United States, the Food and Drug Administration PET MPI study, most Japanese PET facilities are using adenosine as a vasodilator agent, which involves an additional cost for PET MPI study (2) . Although 13 N-NH3 has a relatively short physical half-life (10 minutes), the second 13 N-NH3 administration should be performed 40 to 50 minutes after the first tracer administration. Therefore, clinical stress and rest 13 N-NH3 study usually requires (Table 1) . We hope this update will contribute to the wide clinical use of 13 N-NH3 PET MPI in Japan.
Currently, most facilities use hybrid PET/CT scanners.
However, the current approval of 13 N-NH3 PET MPI is for PET, and simultaneous CT study is not reimbursed. It is expected that this issue will also have to be taken into consideration with regard to the reimbursement policy. (Table 2) . Significantly, this indication included inducible ischemia based on diagnostic testing.
Future directions
The latest JMHLW approvals of cardiac/cardiovascular PET add the diagnosis of great arteritis and increased 
